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1University Hospital Mainz, ACURA Rheumatology Center, Bad Kreuznach, Germany; 2University of North Carolina, Chapel Hill, NC, USA;
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Practicing physicians have requested efficacy and safety data for belimumab, when used with
specific systemic lupus erythematosus (SLE) medications. This was a post hoc analysis of
pooled efficacy and safety data from patients who received belimumab 10mg/kg plus standard
of care (SoC) or placebo (SoC) in two Phase III, randomized trials, BLISS-52 and BLISS-76.
Patients were categorized into four groups based on baseline concomitant medication usage:
steroids only; antimalarials (AM) only; steroidsþAM; or steroidsþAMþ immunosuppressants
(IS). The primary endpoint was the SLE Responder Index (SRI) at Week 52. SRI over time
and individual SRI components were secondary endpoints. Time to first flare and changes in
concomitant medications were exploratory endpoints. Safety was assessed using adverse event
(AE) reporting. Across 834 patients, steroidsþAM was the largest group (n¼ 346, 41.5%)
and AM only was the smallest (n¼ 77, 9.2%). Disease duration was shortest in the
steroidsþAM group (5.7 years vs 6.4–7.1 years); SELENA-SLEDAI scores were similar
across groups. At Week 52, the percentage of SRI responders was greatest in the
steroidsþAM group for belimumab 10mg/kg (59%) compared with placebo (44%); treat-
ment response and SRI component improvements were also observed across other groups.
The probability of experiencing an SLE flare was reduced in the steroids-only group for
patients who received belimumab 10mg/kg compared with placebo (64.3% vs 78.1%;
hazard ratio 0.64; 95% confidence interval: 0.42–0.96). There was little or no change in
daily AM or IS dose in any group. For all groups, there was a general decrease in steroid
dose over time; a quarter to a third of patients experienced decreased steroid doses at Week 52.
The overall safety profile was similar across treatment arms and concomitant medication
groups, with the exception of serious AEs in the steroidsþAM group (belimumab 10mg/kg
16%, placebo 8%). The efficacy and safety of belimumab in combination with SoC was
demonstrated for various groupings of steroids, AM and IS. These findings may improve
the understanding of the safety and efficacy of adding belimumab to different
treatments. Lupus (2016) 25, 1587–1596.
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Introduction
Systemic lupus erythematosus (SLE) is a chronic
autoimmune disease associated with increased mor-
bidity and mortality.1 The clinical manifestations of
SLE are varied and affect several organ systems;
renal disease and skin and musculoskeletal
involvement are frequently reported.1 SLE has a
complex immunological pathology, culminating in
the deposition of autoantibodies and ensuing tissue
damage.2 For many years, lupus standard of care
(SoC) has routinely included antimalarials (AM),
immunosuppressants (IS) and steroids, alone or in
combination.1
In 2011, the recombinant human monoclonal
antibody, belimumab, was licensed for intravenous
(IV) use in autoantibody-positive adults with active
SLE as add-on therapy to SoC.3 Belimumab targets
and inhibits the cytokine B lymphocyte stimulator
(BLyS),4 which is involved in the selection and sur-
vival of B cells and thus production of
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autoantibodies.5 The efficacy and safety of belimu-
mab have been demonstrated in two large, multi-
center, randomized, controlled trials, A Study of
Belimumab in Subjects with Systemic Lupus
Erythematosus (BLISS)-526 and BLISS-76.7 The
patient population included adults with active
SLE who were autoantibody positive, and receiving
SoC. The primary efficacy endpoint was the SLE
Responder Index (SRI)8 response rate at Week 52.
As belimumab is prescribed as an add-on ther-
apy to SoC, physicians have requested data regard-
ing the efficacy and safety of belimumab 10mg/kg
in combination with typical groupings of concomi-
tant SLE medications. We conducted a post hoc
pooled analysis of the BLISS-52 and BLISS-76 stu-
dies to examine the efficacy and safety of belimu-
mab 10mg/kg IV used in combination with AM, IS
and steroids.
Methods
Study design
This post hoc study (GSK study identifier: 201224)
was a pooled analysis of efficacy and safety data
from patients who received belimumab 10mg/kg
plus SoC compared with placebo (SoC) in the two
Phase III, randomized trials BLISS-52 (NCT0
0424476; GSK study identifier: BEL110752)6 and
BLISS-76 (NCT00410384; GSK study identifier:
BEL110751).7
Details of the BLISS-52 and BLISS-76 trials
have been described.6,7 Briefly, patients were ran-
domized to receive belimumab 1mg/kg IV, belimu-
mab 10mg/kg IV (approved dose) or placebo, plus
SoC, for 52 or 76 weeks, respectively. This analysis
was based on the belimumab 10mg/kg and placebo
arm data through Week 52. Changes in concomi-
tant medication use were permitted in the BLISS
trials (Figure 1). Authors defined the concomitant
medication groups using baseline medication data
based on their clinical knowledge and experience.
Concomitant medication usage at study exit was
also described.
Patient population
The primary population was the modified intent-to-
treat population, defined as all patients who were
randomized and treated with at least one dose of
study treatment. Patients were categorized into four
baseline concomitant medication groups: steroids
only; AM only; steroidsþAM; or steroidsþ
AMþ IS.
Study endpoints
The primary endpoint was the SRI at Week 52.8 An
SRI response was defined as a 4-point reduction
from baseline in Safety of Estrogens in Lupus
Erythematosus National Assessment-SLE Disease
Activity Index (SELENA-SLEDAI) score, no wor-
sening (increase of <0.30 points from baseline) in
Physician’s Global Assessment (PGA) and no new
British Isles Lupus Assessment Group (BILAG) A
organ domain score or two new BILAG B organ
domain scores, all comparedwithbaselineatWeek52.
Secondary endpoints included SRI response by
visit, 4 point reduction from baseline in
SELENA-SLEDAI score by visit, change from
baseline in PGA by visit and no new BILAG 1A/2B
organ domain scores by visit.
Exploratory analyses included time to first SLE
flare over 52 weeks (modified SLE Flare Index),
Can increase Maximum of baseline or Week 16
Can increase; can add newa Maximum of baseline or Week 16/24 (BLISS-76/BLISS-52)
Can increase; can add new
Immunosuppressants
Antimalarials
Steroids Within 25% or 5 mg more than baseline No increase
160 24 44 52
Visit week
Figure 1 Permitted changes in concomitant medications during the study.
aAntimalarial treatment could be modified up to Week 16 in BLISS-76 and Week 24 in BLISS-52.
BLISS: A Study of Belimumab in Subjects with Systemic Lupus Erythematosus.
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change in daily dose of concomitant medication,
and SRI for serologically active patients (anti-
double-stranded DNA (anti-dsDNA) positive with
low complement (C3/C4)) by concomitant medica-
tion group.
Safety assessments included treatment-emergent
adverse events (AEs), serious AEs (SAEs) and
study withdrawals.
Statistical analyses
Results for patient characteristics, efficacy end-
points, AEs, and concomitant medication end-
points are presented as mean (standard deviation)
or frequency (percentage), as appropriate. Within
each baseline concomitant medication group,
Kaplan–Meier estimates of the probability of an
SLE flare were calculated and Cox proportional
hazards modeling (adjusting for the covariates:
baseline SELENA-SLEDAI score, baseline pro-
teinuria level, and race) was used to estimate the
hazard ratio (HR) between treatment groups and
the corresponding 95% confidence interval (CI).
No adjustments for multiple comparisons were per-
formed. Analyses were conducted using SAS
Version 9.3 (SAS Institute, Inc., Cary, NC, USA).
Results
Patient population
In the BLISS trials, 1125 patients received placebo
(n¼ 562) or belimumab 10mg/kg (n¼ 563); 418 and
416 patients, respectively, received concomitant
medications at baseline according to the pre-
defined groupings and were included in this post
hoc analysis. The majority of patients received
steroidsþAM (n¼ 346, 41.5%) or steroidsþ
AMþ IS (n¼ 272, 32.6%); the AM-only group
contained the fewest patients (n¼ 77, 9.2%). By
Week 52, 94 (22.5%) patients who received placebo
and 78 (18.8%) who received belimumab withdrew.
The incidence of study withdrawals was compar-
able between treatment arms in the steroidsþAM
and steroidsþAMþ IS groups, lower with belimu-
mab 10mg/kg (19%) than placebo (31%) in the
steroids-only group, and higher with belimumab
10mg/kg (29%) vs placebo (19%) in the AM-only
group. The most common reasons for withdrawal
were AEs, lack of efficacy and patient request
(Figure 2).
Baseline patient demographics and characteris-
tics, by concomitant medication group, are shown
in Table 1. The percentage of patients randomized
to belimumab 10mg/kg or placebo was balanced
within each group. Patients in the steroidsþAM
or steroidsþAMþ IS groups were younger than
those who received steroids or AM only, and
patients in the steroidsþAM group had the short-
est disease duration. Mean SELENA-SLEDAI
scores were similar across groups; a greater propor-
tion of patients receiving belimumab 10mg/kg in
the steroids-only group, and placebo in the
steroidsþAMþ IS group, had a SELENA-
SLEDAI score 10, compared with other groups.
The percentage of patients who were serologically
active (i.e. anti-dsDNA positive with low C3/C4)
ranged from 33% to 68% across groups and treat-
ment arms.
Primary endpoint: SRI response at Week 52
At Week 52, the percentage of patients with an SRI
response was numerically higher for belimumab
10mg/kg compared with placebo for all groups
(Figure 3). The SRI response treatment difference
was greatest in the steroidsþAM group (59% vs
44%: odds ratio (OR) 2.04 (95% CI: 1.30–3.20)).
A treatment difference was also observed in the ster-
oids-only group (59% vs 49%: OR 1.42 (95% CI:
0.71–2.82)) and steroidsþAMþ IS group (42% vs
32%; OR 1.65 (95% CI: 0.99–2.74)) The AM-only
group had the smallest difference between treatment
arms (40% vs 38%: OR 1.10 (95% CI: 0.42–2.91)).
Secondary endpoints
Numerically more patients who received belimumab
10mg/kg compared with placebo had an SRI
response at Week 12 in the steroidsþAM group
(51% vs 41%) and in the steroids-only group
(51% vs 44%). The AM-only group had the smallest
difference at Week 12 (33% vs 28%) and in the
steroidsþAMþ IM group there were fewer respon-
ders in the belimumab arm vs placebo (33% vs
42%). At Week 24, a similar pattern was observed
across treatment arms, except there were slightly
more responders in the belimumab arm vs placebo
in the steroidþAMþ IS group (49% vs 45%).
The percentage of patients with a 4-point
reduction from baseline in SELENA-SLEDAI
score was higher for belimumab 10mg/kg, com-
pared with placebo, in the steroidsþAM group at
Week 24 and Week 52 (Figure 4(a)). A treatment
response was also observed in the steroids-only and
steroidsþAMþ IS groups. At Week 52, there was
a greater mean reduction from baseline in PGA
score for belimumab 10mg/kg, compared with pla-
cebo, in the AM-only and steroidsþAM groups
(Figure 4(b)). The percentage of patients with no
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new BILAG 1A/2B score was greater for those in
the steroidsþAMþ IS group who received belimu-
mab 10mg/kg, compared with placebo
(Figure 4(c)). A treatment response was also
observed in the steroids only and steroidþAM
groups, but not in the AM-only group.
Time to first flare
By Week 52, the probability of experiencing an
SLE flare in the steroids-only group for patients
who received belimumab 10mg/kg compared with
placebo was 64.3% vs 78.1% (HR 0.64; 95% CI:
0.42–0.96). In all other groups, the difference
between treatment arms in risk of SLE flare was
smaller (Table 2).
Changes in concomitant medications
The majority of patients received the same group-
ings of concomitant medications at the beginning
and end of the study (steroids-only group, 93%;
AM-only group, 87%; steroidsþAM group,
87%; steroidsþAMþ IS, 87%). For the majority
of patients (90%) there was no change in AM
dose in any group (data not shown). Similarly,
for the majority of patients (83%) there was no
change in IS dose (data not shown). In the AM-
only group 15 patients initiated steroids before
Week 24 (12 of these were before Week 16) and a
further five patients initiated steroids after Week
24; of these five patients, two completed the study
and three were withdrawn (protocol violation,
investigator decision and lack of efficacy). Mean
steroid dose in all other groups fluctuated over
time, with a general decrease in dose by Week 52
(Figure 5). The percentage of patients who
decreased steroids at each time point increased
over time for both treatment arms (Week 52: ster-
oids-only group, 31% placebo, 27% belimumab;
steroidsþAM group, 22% placebo, 33%
Placebo, n=19 (31%)
- Patient request, 4 (7%)
- AE, 6 (10%)
- Lack of efficacy, 2 (3%)
- Lack of compliance, 0
- Lost to F/U, 1 (2%)
- Protocol violation, 4 (7%)
- Investigator decision, 0 
- Other, 2 (3%)
Belimumab 10 mg/kg, n=15 (19%)
- Patient request, 3 (4%)
- AE, 4 (5%)
- Lack of efficacy, 6 (8%)
- Lack of compliance, 0
- Lost to F/U, 1 (1%)
- Protocol violation, 0
- Investigator decision, 1 (1%)
- Other, 0
Withdrawn
Placebo, n=6 (19%)
- Patient request, 1 (3%)
- AE, 1 (3%)
- Lack of efficacy, 3 (9%)
- Lack of compliance, 0
- Lost to F/U, 0
- Protocol violation, 0
- Investigator decision, 1 (3%)
- Other, 0
Belimumab 10 mg/kg, n=13 (29%)
- Patient request, 4 (9%)
- AE, 4 (9%)
- Lack of efficacy, 0
- Lack of compliance, 1 (2%)
- Lost to F/U, 2 (4%)
- Protocol violation, 1 (2%)
- Investigator decision, 1 (2%)
- Other, 0
Withdrawn
Placebo, n=38 (20%)
- Patient request, 8 (4%)
- AE, 12 (6%)
- Lack of efficacy, 10 (5%)
- Lack of compliance, 2 (1%)
- Lost to F/U, 3 (2%)
- Protocol violation, 2 (1%)
- Investigator decision, 1 (<1%)
- Other, 0
Belimumab 10 mg/kg, n=27 (17%)
- Patient request, 2 (1%)
- AE, 9 (6%)
- Lack of efficacy, 7 (4%)
- Lack of compliance, 0
- Lost to F/U, 1 (<1%)
- Protocol violation, 0
- Investigator decision, 1 (<1%)
- Other, 7 (4%)
Withdrawn
Placebo, n=31 (22%)
- Patient request, 6 (4%)
- AE, 8 (6%)
- Lack of efficacy, 7 (5%)
- Lack of compliance, 0
- Lost to F/U, 1 (<1%)
- Protocol violation, 4 (3%)
- Investigator decision, 3 (2%)
- Other, 2 (1%)
Belimumab 10 mg/kg, n=23 (17%)
- Patient request, 2 (2%)
- AE, 6 (5%)
- Lack of efficacy, 7 (5%)
- Lack of compliance, 1 (<1%)
- Lost to F/U, 3 (2%)
- Protocol violation, 3 (2%)
- Investigator decision, 1 (<1%)
- Other, 0
Withdrawn
Steroids only
Placebo, n=61
Belimumab 10 mg/kg, n=78
AM only
Placebo, n=32
Belimumab 10 mg/kg, n=45  
Steroids + AM
Placebo, n=186
Belimumab 10 mg/kg, n=160
Steroids + AM + IS
Placebo, n=139
Belimumab 10 mg/kg, n=133
Excludeda
Placebo, n=144
Belimumab 10 mg/kg, n=147
201224, N=1125 
Placebo, n=562
Belimumab 10 mg/kg, n=563 
BLISS-52 ITT
Placebo, n=287
Belimumab 10 mg/kg, n=290 
BLISS-76 ITT
Placebo, n=275
Belimumab 10 mg/kg, n=273
Figure 2 Patient disposition.
aPatients excluded as they did not receive steroids, AM or IS.
AE: adverse event; AM: antimalarial; BLISS: A Study of Belimumab in Subjects with Systemic Lupus Erythematosus; F/U: follow-
up; IS: immunosuppressant; ITT: intent-to-treat.
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belimumab; steroidsþAMþ IS, 35% placebo,
40% belimumab). In these groups, the percentages
of patients with increases in steroid doses at Week
52 were lower than the percentages who reported a
decrease (11% at Week 52). In the steroids-only
group, four patients initiated AM (all before Week
24) and five patients initiated IS before Week 24.
SRI response in serologically active patients
At Week 52, the percentage of serologically active
patients with a SRI response was numerically
greater in those treated with belimumab 10mg/kg
compared with placebo in the steroids only group
(55% vs 32%), the steroidsþAM (60% vs 42%)
and steroidsþAMþ IS groups (42% vs 25%)
(Figure 6). The treatment difference was smallest
for the AM-only group (40% vs 36%).
Safety
Overall, the incidence of AEs was comparable
between treatments within each group (Table 3).
The most commonly reported treatment-emergent
AEs across all groups (occurring in >10% of
patients in either treatment arm) were headache,
upper respiratory tract infection, arthralgia, naso-
pharyngitis, urinary tract infection, diarrhea,
nausea and fatigue. Withdrawals due to AEs were
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Figure 4 Secondary endpoints by visit: (a) Percentage of patients with a 4-point reduction in SELENA-SLEDAI. (b) Mean
change from baseline in PGA score. (c) Percentage of patients with a new BILAG 1A/2B score.
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AM: antimalarial; BILAG, British Isles Lupus Assessment Group; IS: immunosuppressant; PGA: Physician’s Global Assessment;
SELENA-SLEDAI: Safety of Estrogen in Lupus National Assessment Systemic Lupus Erythematosus Disease Activity Index.
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consistent across treatment arms and concomitant
medication groups.
The incidence of SAEs was comparable between
treatment arms within each group, with the excep-
tion of the steroidsþAM group (belimumab
10mg/kg, 16% vs placebo, 8%) (Table 3).
In serologically active patients, the incidence of
AEs was comparable to the overall population, and
between treatment arms within each group (ster-
oids-only group, 93% placebo, 94% belimumab;
AM-only group, 100% both treatment arms;
steroidsþAM group, 90% placebo, 92% belimu-
mab; and steroidsþAMþ IS, 97%, both treatment
arms). The incidence of SAEs in serologically active
patients was also consistent with the overall
population.
Discussion
This post hoc analysis from the BLISS trials exam-
ined the efficacy and safety of belimumab 10mg/kg
administered with standard SLE care in the follow-
ing groups: steroids only, AM only, AMþ IS,
steroidsþAMþ IS. For all groups, at Week 52, a
numerically greater SRI response was observed
with belimumab 10mg/kg compared with placebo;
this treatment response was greatest for the
AMþ steroids group, whereas the AM only group
demonstrated the smallest benefit from the addition
of belimumab. These data are similar to previous
post hoc analyses that suggested patients who
received steroids at baseline benefited more from
the addition of belimumab than those who did
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Figure 5 Mean steroid dose over time by concomitant medication group.
AM: antimalarial; IS: immunosuppressant; SE: standard error.
Table 2 Time to first flare
Concomitant medications group Treatment arm
Probability of an event
(95% CI) by Week 52, % Hazard ratio (95% CI)
Steroids only Placebo (n¼ 61) 78.1 (67.0, 87.6) 0.64 (0.42, 0.96)
Belimumab 10mg/kg (n¼ 78) 64.3 (53.6, 74.9)
AM only Placebo (n¼ 32) 84.4 (70.0, 94.3) 0.82 (0.48, 1.38)
Belimumab 10mg/kg (n¼ 45) 81.6 (68.3, 91.8)
SteroidsþAM Placebo (n¼ 186) 80.3 (74.2, 85.8) 0.83 (0.65, 1.06)
Belimumab 10mg/kg (n¼ 160) 71.2 (63.9, 78.2)
SteroidsþAMþ IS Placebo (n¼ 139) 87.9 (81.7, 92.7) 0.81 (0.62, 1.05)
Belimumab 10mg/kg (n¼ 133) 82.3 (75.3, 88.3)
AM: antimalarial; CI: confidence interval; IS: immunosuppressant.
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not.9 Across 52 weeks of treatment, SRI response
was consistently greater with belimumab 10mg/kg
compared with placebo in the steroids-only group.
In the steroidsþAM and steroidsþAMþ IS
groups, SRI response was higher with belimumab
10mg/kg compared with placebo from Week 8 and
Week 16, respectively. Overall, the trends in SRI
response, individual components of the SRI and
time to first flare were similar across the groups,
regardless of baseline concomitant medication
usage, with the exception of the AM-only group.
The safety profile was similar between belimu-
mab and placebo for all groups, with the exception
of SAEs in the steroidsþAM group, which were
higher with belimumab compared with placebo.
The rate of withdrawals was higher in the belimu-
mab 10mg/kg group compared with placebo for
patients receiving AM alone. These withdrawals
were largely due to patient request or as a result
of AEs, and are consistent with the efficacy results
where the AM-only group demonstrated the smal-
lest benefit from the addition of belimumab.
Changes in concomitant medications were subject
to BLISS protocol restrictions. Despite the lack of a
protocol-mandated steroid taper and protocol-
expressed caution on steroid tapering, the percent-
age of patients who decreased steroids at each time
point increased over time for both treatment arms.
The SLE treatment patterns revealed in this analysis
can be considered in the context of the real-world
treatment patterns. A retrospective, observational
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Figure 6 SRI response in serologically active patients (anti-
dsDNA positive with low complement).
Solid lines, belimumab 10mg/kg; dashed lines, placebo.
SRI: Systemic Lupus Erythematosus Responder Index; anti-
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Table 3 Adverse events by concomitant medication group
Steroids only (N¼ 139) AM only (N¼ 77) SteroidsþAM (N¼ 346) SteroidsþAMþ IS (N¼ 272)
Placebo
(n¼ 61)
Belimumab
10mg/kg
(n¼ 78)
Placebo
(n¼ 32)
Belimumab
10mg/kg
(n¼ 45)
Placebo
(n¼ 186)
Belimumab
10mg/kg
(n¼ 160)
Placebo
(n¼ 139)
Belimumab
10mg/kg
(n¼ 133)
Any AEa, n (%) 56 (92) 67 (86) 29 (91) 41 (91) 166 (89) 143 (89) 133 (96) 128 (96)
Headache 8 (13) 10 (13) 3 (9) 6 (13) 47 (25) 33 (21) 32 (23) 30 (23)
Upper respiratory tract infection 10 (16) 12 (15) 8 (25) 10 (22) 26 (14) 18 (11) 35 (25) 25 (19)
Arthralgia 8 (13) 10 (13) 5 (16) 3 (7) 17 (9) 25 (16) 28 (20) 20 (15)
Nasopharyngitis 7 (11) 5 (6) 1 (3) 3 (7) 16 (9) 11 (7) 16 (12) 31 (23)
Urinary tract infection 7 (11) 11 (14) 4 (13) 4 (9) 17 (9) 15 (9) 20 (14) 18 (14)
Diarrhea 5 (8) 8 (10) 5 (16) 2 (4) 12 (6) 11 (7) 13 (9) 18 (14)
Nausea 3 (5) 4 (5) 3 (9) 11 (24) 14 (8) 14 (9) 21 (15) 15 (11)
Fatigue 3 (5) 4 (5) 2 (6) 4 (9) 10 (5) 6 (4) 11 (8) 17 (13)
Bronchitis 1 (2) 6 (8) 3 (9) 4 (9) 9 (5) 12 (8) 5 (4) 15 (11)
Back pain 5 (8) 7 (9) 3 (9) 2 (4) 16 (9) 12 (8) 10 (7) 15 (11)
Pyrexia 8 (13) 5 (6) 1 (3) 4 (9) 11 (6) 12 (8) 13 (9) 14 (11)
Cough 4 (7) 4 (5) 2 (6) 3 (7) 13 (7) 10 (6) 9 (6) 14 (11)
Insomnia 3 (5) 6 (8) 1 (3) 3 (7) 8 (4) 6 (4) 7 (5) 16 (12)
Myalgia 7 (11) 4 (5) 2 (6) 5 (11) 7 (4) 7 (4) 11 (8) 10 (8)
Peripheral edema 3 (5) 3 (4) 2 (6) 2 (4) 11 (6) 8 (5) 11 (8) 13 (10)
Hypertension 11 (18) 3 (4) 2 (6) 1 (2) 15 (8) 12 (8) 12 (9) 8 (6)
Sinusitis 4 (7) 1 (1) 4 (13) 2 (4) 6 (3) 7 (4) 8 (6) 10 (8)
Anemia 7 (11) 5 (6) 1 (3) 0 6 (3) 7 (4) 12 (9) 7 (5)
SAE 13 (21) 13 (17) 3 (9) 4 (9) 14 (8) 26 (16) 29 (21) 26 (20)
AEs leading to withdrawal 6 (10) 4 (5) 1 (3) 4 (9) 12 (6) 9 (6) 8 (6) 6 (5)
aAEs occurring in 10% of patients in any treatment group are listed.
AE: adverse event; AM: antimalarial; IS: immunosuppressant; SAE: serious adverse event.
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cohort study conducted in United States (US)
patients receiving belimumab for the treatment of
SLE reported that 94% of patients used a standard
SLE therapy (corticosteroid, IS, AM) at some time
during the six-month pre-index and six-month post-
index period of the study, with a general decrease in
steroid use observed in the post-index period.10
Similarly, in the OBSErve US study of patients
receiving belimumab, the mean steroid dose and
the percentage of patients who received steroids
decreased over 24 months.11
Several studies have reported sustained efficacy
of belimumab administered in combination with
steroids, with many patients being able to reduce
or even discontinue steroid use over time, sug-
gesting a potential role for belimumab as a ster-
oid-sparing agent, which requires further
investigation.12–14 The concomitant medications
included in this study are representative of those
described in patients with SLE where steroids,
AM and IS have been among the preferred
treatments.15
There are several limitations to the interpret-
ation of these results. In the BLISS trials,
patients were not randomized by concomitant
medications, therefore patient numbers varied
between the groups examined and the study was
not powered to investigate differences between
these groups. The low number of patients in the
AM-only group (n¼ 77) limits the conclusions
that can be drawn from these results, and the
authors feel that discussion of statistical signifi-
cance is not relevant on this basis. Concomitant
medication groups were determined using baseline
data; interestingly, few patients altered treatments
across the year. The BLISS trials restricted when
and how concomitant medications could be
altered, therefore changes in medication and dos-
ages may not be representative of real-world clin-
ical practice. Finally, the BLISS trials did not
collect concomitant medication history prior to
study participation. It would be of interest to
investigate what treatment histories patients had
prior to study enrollment.
In summary, the efficacy of belimumab in com-
bination with SoC was demonstrated for steroids,
alone and in combination with AM and IS. With
the exception of SAEs in the steroidsþAM group,
the safety profile was similar across all medication
groups and treatment arms. These findings may be
helpful in understanding current prescribing prac-
tice trends and may improve the understanding of
the safety and efficacy of adding belimumab to vari-
ous treatments.
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